Evidence map›Paper›PMID 38966207›Full record

ArticlePeerJ2024

Chayisara Phongsuwichetsak, Thummaruk Suksrichavalit, Chawalit Chatupheeraphat, Warawan Eiamphungporn, Sakda Yainoy, Vichanan Yamkamon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chayisara PhongsuwichetsakDepartment of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Thummaruk SuksrichavalitDepartment of Clinical Chemistry, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Chawalit ChatupheeraphatCenter for Research Innovation and Biomedical Information, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.ORCID 0000-0003-4166-3591
Warawan EiamphungpornDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Sakda YainoyDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Vichanan YamkamonDepartment of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.

Funding

Graduate Scholarship of the Faculty of Medical Technology, Mahidol University
6 · The paper itself

Abstract

Background: Prostate cancer (PCa) is one of the causes of death in men worldwide. Although treatment strategies have been developed, the recurrence of the disease and consequential side effects remain an essential concern. Methods: Ethyl acetate was employed to extract the dried bark of Results: EADR exhibited a dose-dependent manner cytotoxic effect on LNCaP cells, with IC Conclusion: The EADR exhibits anti-cancer activity against the LNCaP human prostate cancer cell line by inducing cytotoxicity and apoptosis. Our findings suggest that EADR promotes apoptosis by upregulating pro-apoptotic BAX, whereas downregulation of anti-apoptotic Bcl-2 results in the reduction of MMP and the activation of caspase-3. Of particular interest is the presence of epilupeol, a major compound identified in EADR, which may hold promise as a candidate for the development of therapeutic agents for prostate cancer.

Indexed as

Apoptosisbcl-2-Associated X ProteinCaspase 3DiospyrosPlant ExtractsProstatic NeoplasmsProto-Oncogene Proteins c-bcl-2Antineoplastic Agents, PhytogenicCell Line, TumorHumansMaleMembrane Potential, MitochondrialMitochondriaAntineoplastic Agents, PhytogenicBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanCaspase 3Plant ExtractsProto-Oncogene Proteins c-bcl-2Anticancer activityApoptosisDiospyros rhodocalyx KurzLNCaPProstate cancer

Identifiers

PMID38966207
PMCPMC11223595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.